Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households

Frederik Plesner Lyngse^{1,2,3,*}, Carsten Thure Kirkeby⁴,
Matthew Denwood⁴, Lasse Engbo Christiansen⁵,
Kåre Mølbak^{3,4}, Camilla Holten Møller³,
Robert Leo Skov³, Tyra Grove Krause³,
Morten Rasmussen³, Raphael Niklaus Sieber³,
Thor Bech Johannesen³, Troels Lillebaek^{3,6},
Jannik Fonager³, Anders Fomsgaard³,
Frederik Trier Møller³, Marc Stegger³,
Maria Overvad³, Katja Spiess³,
Laust Hvas Mortensen^{7,8}

January 28, 2022

*Correspondence to Frederik Plesner Lyngse, fpl@econ.ku.dk. Affiliations: ¹Department of Economics & Center for Economic Behaviour and Inequality, University of Copenhagen, Copenhagen, Denmark; ²Danish Ministry of Health, Copenhagen, Denmark; ³Statens Serum Institut, Copenhagen, Denmark; ⁴Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ⁵Department of Applied Mathematics and Computer Science; Dynamical Systems, Technical University of Denmark, Kgs. Lyngby, Denmark; ⁶Global Health Section, UNICEF, Copenhagen, Denmark; ⁷Department of Economics, University of Copenhagen, Copenhagen, Denmark; ⁸Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

1 Abstract

The Omicron SARS-CoV-2 variant of concern (VOC lineage B.1.1.529), which became dominant in many countries during early 2022, includes several subvariants with strikingly different genetic characteristics. Several countries, including Denmark, have observed the two Omicron subvariants: BA.1 and BA.2. In Denmark the latter has rapidly replaced the former as the dominant subvariant.

Based on nationwide Danish data, we estimate the transmission dynamics of BA.1 and BA.2 following the spread of Omicron VOC within Danish households in late December 2021 and early January 2022.

Among 8,541 primary household cases, of which 2,122 were BA.2, we identified a total of 5,702 secondary infections among 17,945 potential secondary cases during a 1-7 day follow-up period. The secondary attack rate (SAR) was estimated as 29% and 39% in households infected with Omicron BA.1 and BA.2, respectively.

We found BA.2 to be associated with an increased susceptibility of infection for unvaccinated individuals (Odds Ratio (OR) 2.19; 95%-CI 1.58-3.04), fully vaccinated individuals (OR 2.45; 95%-CI 1.77-3.40) and booster-vaccinated individuals (OR 2.99; 95%-CI 2.11-4.24), compared to BA.1. We also found an increased transmissibility from unvaccinated primary cases in BA.2 households when compared to BA.1 households, with an OR of 2.62 (95%-CI 1.96-3.52). The pattern of increased transmissibility in BA.2 households was not observed for fully vaccinated and booster-vaccinated primary cases, where the OR of transmission was below 1 for BA.2 compared to BA.1.

We conclude that Omicron BA.2 is inherently substantially more transmissible than BA.1, and that it also possesses immune-evasive properties that further reduce the protective effect of vaccination against infection, but do not increase its transmissibility from vaccinated individuals with breakthrough infections.

2 Introduction

The current pandemic with SARS-CoV-2 is characterized by continuous emergence of new variants taking over from previous variants as a result of natural selection (Darwin, 1859). Most recently, the Omicron variant of concern (VOC), Pango lineage B.1.1.529, has become the most prevalent in most countries in Europe as well as the rest of the world (Ritchie & Roser, 2020). Of the previously identified Omicron subvariants (Mullen et al., 2022; SSI, 2022), three subvariants have been detected in Denmark, namely BA.1.1, BA.1 and BA.2, where the latter two by far have been the most abundant. BA.1 and BA.2 differ by approximately 40 mutations (Majumdar & Sarkar, 2021) in addition to a key deletion at position 69-70 in the spike region of BA.1 compared to BA.2 (Public Health England, 2022; Chowdhury et al., 2022).

By 1 January 2022, BA.2 accounted for 5% of all subvariants found in England, with an ongoing increase in this proportion (Public Health England, 2022). BA.1 was first detected in Denmark on 25 November 2021, and BA.2 was first detected on 5 December 2021. Since then, the prevalence of BA.2 has been increasing faster than that of BA.1. In week 52 of 2021, BA.2 accounted for around 20% of all Danish SARS-CoV-2 cases; in week 2 in 2022 this had increased to around 45%, indicating that BA.2 carries an advantage over BA.1 within the highly vaccinated population of Denmark. The RT-PCR test used in Denmark does not target the S-gene deletion to detect Omicron cases, but instead targets the spike position L452 Wt (Spiess et al., 2021). Thus in the current set-up, Danish RT-PCR data cannot distinguish between BA.1 and BA.2. However, whole genome sequencing (WGS) is conducted routinely in Denmark (www.covid19genomics.dk), providing the opportunity to identify and differentiate between BA.1 and BA.2.

We have previously used a model of household transmission to quantify the transmissibility of VOCs, and applied this model to show that the Omicron VOC had an advantage over the Delta VOC due to immune evasiveness (Lyngse et al., 2021b).

The increasing numbers of BA.2 cases justify the questions we address in this study;

1) Is there a difference in the household transmission patterns between Omicron VOC

subvariant BA.1 and BA.2; and 2) if there is a difference, is it due to a difference in susceptibility, transmissibility, or both, and could this indicate a difference in immune evasiveness between the subvariants?

3 Methods

3.1 Study design and participants

In this study, we used Danish register data comprising all individuals in Denmark. We linked all individuals to households by their personal identification number. We only included households with 2-6 members to exclude care facilities etc. We linked this with information on all antigen and RT-PCR tests for SARS-CoV-2 from the Danish Microbiology Database (MiBa; Schønning et al. (2021)), and records in the Danish Vaccination Register (Krause et al., 2012). We used data on primary cases from 20 December 2021 to 11 January 2022, and allowed a 7-day follow-up period for potential secondary cases, i.e. until 18 January 2022.

A primary case was defined as the first individual in a household testing positive with an RT-PCR test within the study period and being identified with the Omicron VOC BA.1 or BA.2 by WGS. We followed all tests of other household members in the follow-up period. A positive secondary case was defined by either a positive RT-PCR test or a positive antigen test (Jakobsen et al., 2021). Households were categorized as BA.1 or BA.2 households depending on the WGS result of the sample from the primary case.

In the study period, a total of approximately 25,000 mid- and high-quality SARS-CoV-2 genomes were produced (appendix Table 4) at the time of analysis. Briefly, sequencing of positive SARS-CoV-2 samples was performed using short read Illumina technology (Illumina) with the Illumina COVIDSeq Test kit (Illumina). The library preparation was performed as described by the manufacturer with spike-in of amplicon 64, 70 and 74 from the ARTIC v3 amplicon sequencing panel (<https://artic.network>). Samples were sequenced on either the NextSeq or NovaSeq platforms (Illumina). Consensus sequences

were called using an in-house implementation of IVAR (version 1.3.1) with a custom BCFtools (Li, 2011) command for consensus calling. The resulting consensus sequences were considered for variant calling when containing <3,000 ambiguous sites including N's. Variants were called using Pangolin (version 3.1.17) with PangoLEARN assignment algorithm (version 2022-01-05) on the consensus sequences (O'Toole et al., 2021).

The vaccination status of all individuals was classified into three groups following Lyngse et al. (2021b): i) unvaccinated (including partially vaccinated individuals); ii) fully vaccinated (defined by the vaccine used, Comirnaty (Pfizer/BioNTech): 7 days after second dose; Vaxzevria (AstraZeneca): 15 days after second dose; Spikevax (Moderna): 14 days after second dose; Janssen (Johnson & Johnson): 14 days after vaccination, and 14 days after the second dose for cross vaccinated individuals) or 14 days after previous infection; or iii) booster-vaccinated, defined by 7 days after the booster vaccination, (Pfizer, 2021; Bomze et al., 2021). By 22 December 2021, of all vaccinated individuals in Denmark, 85% were vaccinated with Comirnaty, 14% with Spikevax, 1% with Janssen, and approximately 0% with AstraZeneca (SSI, 2021).

3.2 Statistical analyses

The secondary attack rate (SAR) was defined as the proportion of potential secondary cases within the same household that tested positive between 1-7 days following the positive test of the primary case in that household. We estimated the adjusted odds ratios (OR) for infection in a multivariable logistic regression model. The outcome variable in this model was the binary test result of each potential secondary case. We used the subvariant as an explanatory variable as well as fixed effects for other potentially confounding variables; age and sex of the primary case, age and sex of the potential secondary case, household size (2-6 members), and primary case sample date to control for time related effects. To test if the subvariants behaved differently depending on the immune status of the primary cases (i.e. different transmissibility) and the potential secondary cases (i.e. different susceptibility), we included interactions between household subvariant and vaccination status of the primary cases and the potential secondary cases, respectively.

To investigate the robustness of the results, we conducted a number of additional sensitivity analyses, which can be found in the appendix. Here, we also describe the distribution of BA.1 and BA.2 cases over the study period and the characteristics of samples selected for WGS. We also provide statistics for a 14-day follow-up period. Additionally, we provide measures of model fit and estimates under a number of alternative specifications of the logistic regression model to assess the robustness of the findings, as well as a more detailed investigation of the pairwise OR between vaccination groups for each subvariant.

3.3 Ethical statement

This study was conducted using data from national registers only. According to Danish law, ethics approval is not needed for this type of research. All data management and analyses were carried out on the Danish Health Data Authority's restricted research servers with project number FSEID-00004942. The study only contains aggregated results and no personal data. The study is, therefore, not covered by the European General Data Protection Regulation (GDPR).

3.4 Data availability

The data used in this study are available under restricted access due to Danish data protection legislation. The data are available for research upon reasonable request to The Danish Health Data Authority and Statens Serum Institut and within the framework of the Danish data protection legislation and any required permission from Authorities. We performed no data collection or sequencing specifically for this study. Consensus genome data from the Danish cases are routinely shared publicly at GISAID (www.gisaid.org).

4 Results

We identified 2,122 households with BA.2 comprising a total of 4,587 potential secondary cases, of which 1,792 tested positive within 7 days, resulting in a SAR of 39%. Similarly,

we identified 6,419 households with BA.1 comprising a total of 13,358 potential secondary cases, of which 3,910 tested positive, resulting in a SAR of 29%. The distributions of age, sex, household size and vaccination status in primary and potential secondary cases were broadly comparable between BA.1 and BA.2 households (Table 1).

Table 1: Summary statistics

	Omicron - BA.2				Omicron - BA.1			
	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)
Total, N	2,122	4,587	1,792	39	6,419	13,358	3,910	29
Sex, %								
Male	49	50	49	38	49	50	48	28
Female	51	50	51	40	51	50	52	31
Age, %								
0-10	8	17	19	42	5	17	19	33
10-20	25	18	16	34	23	19	17	26
20-30	23	14	13	38	27	15	16	31
30-40	15	12	18	56	15	11	15	42
40-50	11	18	17	38	12	18	17	27
50-60	11	14	12	32	11	14	10	22
60-70	4	4	3	35	5	4	4	25
70+	3	2	2	30	3	2	2	26
Household size, %								
2	37	17	19	44	40	19	22	33
3	24	23	21	37	25	24	22	27
4	26	36	38	41	23	34	35	31
5	10	18	16	34	9	18	17	28
6	2	6	5	35	2	5	4	23
Immunity, %								
Unvaccinated	21	26	29	43	16	26	30	34
Fully vaccinated / previous infection	52	42	44	41	59	44	47	31
Booster vaccinated	26	32	27	34	25	30	23	22

Notes: The secondary attack rate (SAR) is expressed as a percentage (%). Total numbers (N) is presented in the first row. Summary statistics based on primary cases are shown separately from summary statistics of potential secondary cases, positive secondary cases and SAR. The raw numbers (N) for each category is presented in appendix Table 5. The summary statistics stratified by the primary case level are presented in appendix Tables 6 and 7.

Within 7 days of the identification of the primary cases, 84% of the potential secondary cases had been tested once, regardless of subvariant, and 60-61% had been tested twice (Figure 1, panel a). In households infected with the Omicron BA.2 (red), the SAR was 8% on day 1 and 39% on day 7. Similarly, in households infected with BA.1 (blue), the SAR was 6% and 29%, respectively.

Figure 1: Probability of being tested and testing positive

Notes: Panel (a) shows the probability of potential secondary cases being tested after a primary case has been identified within the household. Panel (b) shows the probability of potential secondary cases that test positive subsequently to a primary case being identified within the household. Note that the latter is not conditional on being tested, i.e. the denominator contains test-negative individuals and untested individuals. The x-axes show the days since the primary case tested positive, and the y-axes show the proportion of individuals either being tested (a) or testing positive (b) with either antigen or RT-PCR tests, stratified for the subvariant of the primary case. The SAR for each day according to the subvariant primary case can be read directly from panel (b). For example, the SAR on day 7 is 39% for BA.2 (red) and 29% for BA.1 (blue), whereas the SAR on day 4 is 30% and 22%, respectively. The shaded areas show the 95% confidence bands clustered on the household level. Appendix Figure 3 presents the two panels with a 14 day follow-up period. Appendix Figure 4 presents the 14 day SAR for Omicron BA.1, BA.2, and Delta VOC, as well as those without a known variant.

We observed a general gradient in both Omicron BA.1 and BA.2 households such that the susceptibility of potential secondary cases was highest among the unvaccinated and lowest among the booster vaccinated, but the effect of vaccination appeared to be lower for Omicron BA.2 than for BA.1 (see Table 2, and the interactions in Figure 6). We observed lower transmissibility in both BA.1 and BA.2 households when the primary case was booster vaccinated rather than fully vaccinated.

Table 2: Effect of Vaccination

	Susceptibility		Transmissibility	
	Omicron BA.2 households	Omicron BA.1 households	Omicron BA.2 households	Omicron BA.1 households
Unvaccinated	1.10 (0.92-1.32)	1.23 (1.09-1.40)	1.21 (0.97-1.50)	0.93 (0.80-1.08)
Fully vaccinated	ref (.)	ref (.)	ref (.)	ref (.)
Booster vaccinated	0.80 (0.67-0.94)	0.65 (0.58-0.73)	0.79 (0.64-0.98)	0.77 (0.70-0.88)
Number of observations	17,945	17,945	17,945	17,945
Number of households	8,541	8,541	8,541	8,541

Notes: This table shows odds ratio estimates for susceptibility and transmissibility by vaccination status. Column 1 shows the susceptibility based on the vaccination status of the potential secondary case, conditional on being in a household infected with BA.2. Column 2 shows the susceptibility based on the vaccination status of the potential secondary case, conditional on being in a household infected with BA.1. Column 3 shows the transmissibility based on the vaccination status of the primary case, conditional on being in a household infected with BA.2. Column 4 shows the transmissibility based on the vaccination status of the primary case, conditional on being in a household infected with BA.1. Note that all estimates are from the same model, but with a different reference category across column 1-4. The estimates are adjusted for age and sex of the primary case, age and sex of the potential secondary case, size of the household, and primary case sample date. The estimates are furthermore adjusted for vaccination status of the potential secondary case and primary case interacted with the household subvariant. 95% confidence intervals are shown in parentheses. Standard errors are clustered on the household level. The odds ratio estimates for the full model are presented in the appendix Table 12, column I.

Relative to Omicron BA.1 households, we found an increased susceptibility for both unvaccinated (OR 2.19; 95%-CI 1.58-3.04), fully vaccinated (OR 2.45; 95%-CI 1.77-3.40) and booster-vaccinated individuals (OR 2.99; 95%-CI 2.11-4.24) in BA.2 households (Table 3). We also observed increased transmissibility in BA.2 households from unvaccinated primary cases when compared to BA.1 households with an OR of 2.62 (95%-CI 1.96-3.52). The pattern of increased transmissibility in BA.2 households was not observed for fully vaccinated and booster-vaccinated primary cases, where the estimates were below 1 for BA.2 compared to BA.1 (Table 3).

Table 3: Relative effect of Omicron VOC BA.2 vs. BA.1

	Susceptibility			Transmissibility		
	Unvaccinated	Fully vaccinated	Booster vaccinated	Unvaccinated	Fully vaccinated	Booster vaccinated
Omicron BA.2 households	2.19 (1.58-3.04)	2.45 (1.77-3.40)	2.99 (2.11-4.24)	2.62 (1.96-3.52)	0.60 (0.42-0.85)	0.62 (0.42-0.91)
Omicron BA.1 households	ref (.)	ref (.)	ref (.)	ref (.)	ref (.)	ref (.)
Number of observations	17,945	17,945	17,945	17,945	17,945	17,945
Number of households	8,541	8,541	8,541	8,541	8,541	8,541

Notes: This table shows odds ratio estimates for the effect of living in a household infected with BA.2 relative to BA.1. Column 1 and 4 shows the relative transmission of BA.2, conditional on being unvaccinated. Column 2 and 5 shows the relative transmission of BA.2, conditional on being fully vaccinated. Column 3 and 6 shows the relative transmission of BA.2, conditional on being booster vaccinated. Note, all estimates are from the same model, but with a different reference category across column 1-6. The estimates are adjusted for age and sex of the primary case, age and sex of the potential secondary case, size of the household, and primary case sample date. The estimates are furthermore adjusted for vaccination status of the potential secondary case and primary case interacted with the household subvariant. 95% confidence intervals are shown in parentheses. Standard errors are clustered on the household level. The odds ratio estimates for the full model are presented in Appendix Table 12, column I.

In the appendix, where we allowed for a 14-day follow-up, we found a 14-day SAR of 42% for BA.2 and 36% for BA.1 (appendix Figure 3).

The distribution of sample Ct values for unvaccinated primary cases showed that the viral load was overall higher for BA.2 cases than for BA.1 cases. This was not the case for fully vaccinated and booster-vaccinated individuals, where the distribution appeared to be the same (appendix Figure 5 and appendix Table 8).

5 Discussion

The present study shows that infection with the Omicron BA.2 subvariant generally lead to a higher SAR compared to BA.1 across all groups of sex, age, household sizes and immunity groups (Table 1). Furthermore, we found that booster-vaccinated individuals had a reduced susceptibility and transmissibility for both BA.1 and BA.2 compared to fully vaccinated individuals (Table 2). Efficient transmission to vaccinated individuals corroborates previous findings that the Omicron VOC possess immune evasive properties (Zhang et al., 2021; Lyngse et al., 2021b; Ferguson et al., 2021; Planas et al., 2021). However, both booster-vaccinated individuals and fully-vaccinated individuals had reduced susceptibility and transmissibility compared to unvaccinated individuals for both subvari-

ants, suggesting that the effectiveness of vaccines remains significant (appendix Figure 6).

Both unvaccinated, fully vaccinated and booster-vaccinated individuals had a higher susceptibility for BA.2 compared to BA.1, indicating an inherent increased transmissibility of BA.2 (Table 3). However, the relative increase in susceptibility was significantly greater in vaccinated individuals compared to unvaccinated individuals (appendix Figure 6), which points towards immune evasive properties of the BA.2 conferring an even greater advantage for BA.2 in a highly vaccinated population such as Denmark. Because previous studies of the Omicron VOC has focused on the BA.1 (Pearson et al., 2021; Planas et al., 2021), new studies are needed to further investigate these properties for BA.2.

Unvaccinated individuals had a higher transmissibility with BA.2 compared to BA.1. Contrary to this, fully vaccinated and booster-vaccinated individuals had a reduced transmissibility, due to a significant negative interaction between subvariant and booster/fully vaccinated individuals compared to unvaccinated individuals (appendix Figure 6). This indicates that after a breakthrough infection, vaccination protects against further transmission, and more so for BA.2 than BA.1. This mechanism is only possible to identify in studies that take into account the exposure of individuals.

A potential mechanism for the higher transmissibility of unvaccinated individuals infected with BA.2 compared to BA.1 could be a higher viral load (appendix 7.3). No such difference was found for fully or booster-vaccinated individuals, which could be a result of a lower viral load in vaccinated individuals with a breakthrough infection (Puhach et al., 2022; Levine-Tiefenbrun et al., 2021; Lyngse et al., 2022).

The higher susceptibility and transmissibility among unvaccinated will likely result in even more extensive transmission of BA.2 in unvaccinated children in school settings and day care.

This study has a number of strengths. Firstly, Denmark is, to the best of our knowledge, the only country in the world that have been able to identify a large amount of both BA.1 and BA.2 cases in December 2021 and January 2022. Secondly, any bias introduced

in the identification of the subvariants will presumably affect both BA.1 and BA.2 in a similar way. Third, this study draws on exhaustive population registers with a high quality of information covering the whole population. Fourth, potential secondary cases were frequently being tested: 84% one time, and 60-61% two times.

Some limitations apply to this study. The study period runs over Christmas 2021 and New Year's Eve 2021/22, which are public holidays in Denmark. Despite government advice to limit social activity, it is likely that there has been considerable social mixing with family and friends outside the households during this period. Social mixing over the holidays in conjunction with the high incidence levels in Denmark during this period likely means that some secondary cases in this study are actually misclassified co-primary cases, i.e. infections picked up outside the household and testing positive after each other. However, this potential bias would be applicable to both subvariants. Moreover, our estimates were robust when only including primary cases from 5-11 January 2022 (appendix Table 12, model II) and when only including secondary cases found on day 2-7 or 3-7 (appendix Table 13, model VII and VIII).

The present household study showed a transmission advantage of Omicron BA.2 over BA.1. Although vaccinations, in particular booster vaccinations, did protect against infection, the 2.45 (fully vaccinated) and 2.99 (booster vaccinated) fold higher odds of infection in BA.2 households indicate that BA.2 as a phenotype represents a further step in immune evasion in the Omicron lineage. However, it is likely that this change came with an evolutionary cost for BA.2. To our surprise, we found a decreased transmissibility of BA.2 relative to BA.1 among fully vaccinated and booster vaccinated, with estimates of 0.60 and 0.62, respectively. Based on such a considerable loss in transmissibility among vaccinated individuals, it is not straightforward to predict the future trajectory of BA.2 relative to BA.1 or other potentially emerging variants.

Evolution of SARS-CoV-2 variants, including the Omicron VOC, is constantly evolving, especially during the current record high transmission in many countries. For public health, it is reassuring that BA.2, like BA.1, seems to be associated with favorable out-

comes relative to the Delta variant, and that vaccines protect in particular against hospital admissions and severe illness (Wolter et al., 2022; Bager et al., 2022). Even with the emergence of BA.2, vaccines have an effect against infection, transmission and severe disease, although reduced compared to the ancestral variants. The combination of high incidence of a relative innocuous subvariant has raised optimism (Sundhedsministeriet, 2022). It is, however, important to follow the future evolution of the BA.2 subvariant closely, as well as future emergent subvariants. Thus, it is critical to maintain rapid high-quality WGS with random sampling as part of surveillance to continuously support the risk assessment of new variants, their impact on public health and to inform public health policy makers, when navigating during a pandemic.

References

- Bager, P., Wohlfahrt, J., Bhatt, S., Edslev, S. M., Sieber, R. N., Ingham, A. C., Stegger, M., Legarth, R., Holten Møller, C., Skov, R. L., Valentiner-Branth, P., Overvad, M., Gram, M. A., Lomholt, F. K., Hallundbæk, L., Espensen, C. H., Gubbels, S. M., Voldstedlund, M., Karakis, M., Møller, K. L., Olsen, S. S., Fischer, T. K., Barrella Harboe, Z., Johannesen, C. K., van Wijhe, M., Holler, J. G., Simonsen, L., Dessau, R. B. C., Friis, M. B., Fuglsang-Damgaard, D., Pinholt, M., Kirkby, N. S., Thomsen, M. K., Sydenham, T. V., Coia, J. E., Marmolin, E. S., Fomsgaard, A., Fonager, J., Rasmussen, M., Spiess, K., Marving, E., Cohen, A., Larsen, N. B., Lillebaek, T., Ullum, H., Mølbak, K., & Grove Krause, T. (2022). Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study. *SSRN*.
- Bomze, D., Sprecher, E., & Gamzu, R. (2021). Effect of a nationwide booster vaccine rollout in Israel on SARS-CoV-2 infection and severe illness in young adults. *Travel medicine and infectious disease*, 44, 102195.
- Chowdhury, S., Bappy, M. H., Chowdhury, S., Chowdhury, M. S., & Chowdhury, N. S. (2022). Omicron Variant (B. 1.1. 529) of SARS-CoV-2, A Worldwide Public Health Emergency! *European Journal of Clinical Medicine*, 3(1), 5–9.
- Darwin, C. (1859). *On the Origin of Species by Means of Natural Selection*. London: John Murray.
- Ferguson, N., Ghani, A., Cori, A., Hogan, A., Hinsley, W., & Volz, E. (2021). Report 49: Growth, population distribution and immune escape of Omicron in England. *Imperial College London (16-12-2021)*, doi: <https://doi.org/10.25561/93038>.
- Jakobsen, K. K., Schmidt Jensen, J., Todsén, T., Kirkby, N., Lippert, F., Vangsted, A.-M., Klokke, M., & von Buchwald, C. (2021). Accuracy of anterior nasal swab rapid antigen tests compared with RT-PCR for massive SARS-CoV-2 screening in low prevalence population. *APMIS*.

- 269 Krause, T. G., Jakobsen, S., Haarh, M., & Mølbak, K. (2012). The Danish vaccination
270 register. *Eurosurveillance*, 17(17), 20155.
- 271 Levine-Tiefenbrun, M., Yelin, I., Katz, R., Herzel, E., Golan, Z., Schreiber, L., Wolf, T.,
272 Nadler, V., Ben-Tov, A., Kuint, J., et al. (2021). Decreased SARS-CoV-2 viral load
273 following vaccination. *MedRxiv*.
- 274 Li, H. (2011). A statistical framework for SNP calling, mutation discovery, association
275 mapping and population genetical parameter estimation from sequencing data. *Bioin-*
276 *formatics*, 27(21), 2987–2993.
- 277 Lyngse, F. P., Mølbak, K., Denwood, M., Christiansen, L. E., Møller, C. H., Rasmussen,
278 M., Cohen, A. S., Stegger, M., Fonager, J., Sieber, R., et al. (2022). Effect of Vaccination
279 on Household Transmission of SARS-CoV-2 Delta VOC. *medRxiv*.
- 280 Lyngse, F. P., Mølbak, K., Skov, R. L., Christiansen, L. E., Mortensen, L. H., Albertsen,
281 M., Møller, C. H., Krause, T. G., Rasmussen, M., Michaelsen, T. Y., et al. (2021a).
282 Increased transmissibility of SARS-CoV-2 lineage B. 1.1. 7 by age and viral load. *Nature*
283 *Communications*, 12(1), 1–8.
- 284 Lyngse, F. P., Mortensen, L. H., Denwood, M. J., Christiansen, L. E., Møller, C. H.,
285 Skov, R. L., Spiess, K., Fomsgaard, A., Lassaunière, R., Rasmussen, M., Stegger, M.,
286 Nielsen, C., Sieber, R. N., Cohen, A. S., Møller, F. T., Overvad, M., Mølbak, K.,
287 Krause, T. G., & Kirkeby, C. T. (2021b). SARS-CoV-2 Omicron VOC Transmission in
288 Danish Households. *MedRxiv*.
- 289 Majumdar, S. & Sarkar, R. (2021). Mutational and phylogenetic analyses of the two
290 lineages of the Omicron variant. *Journal of medical virology*.
- 291 Mullen, J. L., Tsueng, G., Latif, A. A., Alkuzweny, M., Cano, M., Haag, E., Zhou,
292 Jerry Zeller, M., Hufbauer, E., Matteson, N., Andersen, K. G., Wu, C., Su, A. I.,
293 Gangavarapu, K., Hughes, L. D., & for Viral Systems Biology outbreak, C. (2022).
294 SARS-CoV-2 (hCoV-19) Mutation Reports.

O'Toole, Á., Hill, V., Pybus, O. G., Watts, A., Bogoch, I. I., Khan, K., Messina, J. P.,
COVID, T., et al. (2021). Tracking the international spread of SARS-CoV-2 lineages
B. 1.1. 7 and B. 1.351/501Y-V2. *Wellcome Open Research*, 6.

Pearson, C. A., Silal, S. P., Li, M. W., Dushoff, J., Bolker, B. M., Abbott, S., van
Schalkwyk, C., Davies, N. G., Barnard, R. C., Edmunds, W. J., et al. (2021). Bounding
the levels of transmissibility & immune evasion of the Omicron variant in South Africa.
medRxiv.

Pfizer (2021). Pfizer and Biontech submit request to amend U.S. FDA
emergency use authorization of their Covid-19 vaccine booster to in-
clude all individuals 18 and older) https://cdn.pfizer.com/pfizercom/2021-11/Booster_10K_Efficacy_EUA_Submission_Statement_Final_11921.pdf?linkId=139453336
(Accessed 2021-12-21).

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J.,
Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2021). Considerable escape
of SARS-CoV-2 Omicron to antibody neutralization. *Nature*, (pp. 1–7).

Public Health England (2022). SARS-CoV-2 variants of concern and variants under in-
vestigation in England. *technical briefing 34*.

Puhach, O., Adea, K., Hulo, N., Sattonnet-Roche, P., Genecand, C., Iten, A., Bausch,
F. J., Kaiser, L., Vetter, P., Eckerle, I., et al. (2022). Infectious viral load in unvaccinated
and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. *medRxiv*.

R Core Team (2021). *R: A Language and Environment for Statistical Computing*. R
Foundation for Statistical Computing, Vienna, Austria.

Ritchie, H. & Roser, M. (2020). Share of SARS-CoV-2 sequences that are the
omicron variant, Jan 21, 2022. https://ourworldindata.org/grapher/covid-cases-omicron?country=GBR_FRA_BEL_DEU_ITA_ESP_USA_ZAF_BWA_AUS.

Schønning, K., Dessau, R. B., Jensen, T. G., Thorsen, N. M., Wiuff, C., Nielsen, L.,
Gubbels, S., Denwood, M., Thygesen, U. H., Christensen, L. E., Møller, C. H., Møller,

J. K., Ellermann-Eriksen, S., Østergaard, C., Lam, J. U. H., Abushalleeh, N., Meaidi, M., Olsen, S., Mølbak, K., & Voldstedlund, M. (2021). Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark. *APMIS*, 129(7), 438–451.

Spiess, K., Gunalan, V., Marving, E., Nielsen, S. H., Joergensen, M. G., Fomsgaard, A. S., Nielsen, L., Alfaro-Nunez, A., Karst, S. M., Mortensen, S., et al. (2021). Rapid surveillance platforms for key SARS-CoV-2 mutations in Denmark. *medRxiv*.

SSI (2021). Covid-19 Vaccinatedashboard, (accessed 2021-12-22). <https://experience.arcgis.com/experience/9824b03b114244348ef0b10f69f490b4/page/Regionalt/>.

SSI (2022). Now, an Omicron variant, BA.2, accounts for almost half of all Danish Omicron-cases.

Sundhedsministeriet (2022). Alle restriktioner udløber d. 31. januar.

Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022). Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. *The Lancet*.

Zhang, X., Wu, S., Wu, B., Yang, Q., Chen, A., Li, Y., Zhang, Y., Pan, T., Zhang, H., & He, X. (2021). SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. *Signal transduction and targeted therapy*, 6(1), 1–3.

Acknowledgements

We thank Statens Serum Institut and The Danish Health Data Authority for collecting and providing access to data access. We also thank the rest of the Expert Group for Mathematical Modeling of COVID-19 at Statens Serum Institut for helpful discussions. The authors wish to thank the Danish Covid-19 Genome Consortium for genotyping SARS-CoV-2 positive samples. We thank Simon Killebæk Andersen (Department of Economics, University of Copenhagen) for proofreading the manuscript.

Funding

Frederik Plesner Lyngse: Independent Research Fund Denmark (Grant no. 9061-00035B.); Novo Nordisk Foundation (grant no. NNF17OC0026542); the Danish National Research Foundation through its grant (DNRF-134) to the Center for Economic Behavior and Inequality (CEBI) at the University of Copenhagen. Laust Hvas Mortensen is supported in part by grants from the Novo Nordisk Foundation (grant no. NNF17OC0027594, NNF17OC0027812).

Contributions

FPL performed all data analyses. MD calculated the contrasts between vaccination groups. FPL, CTK and LHM wrote the first draft. All other authors contributed to the discussion, revised the first draft and approved the submitted version.

Competing interests

The authors declare no competing interests.

Supplementary Appendix

6 Background

This section provides some background characteristics for all of Denmark, i.e. not restricted to the study sample used for the analysis of household transmission.

6.1 Number of tests

Table 4 shows the number of antigen (AG) tests and RT-PCR tests in Denmark from 1 December 2021 to 19 January 2022. The table also provides information on the number of successfully sequenced positive RT-PCR tests by SARS-CoV-2 variant, including their relative proportion. On 20 December 2021, Omicron BA.2 comprised 5% of all infections, and Omicron BA.1 comprised 64%, while Delta comprised 30%. By 11 January 2022, the proportions were 47%, 53%, and 0%, respectively.

Table 4: Number of tests in Denmark, 1 December 2021–19 January 2022

Sample date	AG tests		RT-PCR tests		Variant					
	Tests N	Positives N	Tests N	Positives N	Omicron BA.2 N	%	Omicron BA.1 N	%	Delta N	%
01-12-2021	177,466	1,946	188,052	4,874	0	0	56	2	2,298	98
02-12-2021	217,978	1,908	216,548	4,960	0	0	43	2	2,630	98
03-12-2021	237,466	1,891	189,592	5,599	0	0	34	1	2,342	99
04-12-2021	143,557	1,566	142,053	5,524	0	0	58	2	2,910	98
05-12-2021	144,767	2,133	149,098	5,401	<5	0	102	3	3,330	97
06-12-2021	228,350	2,882	211,711	7,546	0	0	211	5	4,206	95
07-12-2021	233,073	2,778	211,038	7,814	0	0	203	10	1,825	90
08-12-2021	239,456	2,885	207,141	7,088	0	0	199	11	1,533	89
09-12-2021	268,385	2,807	245,057	7,092	0	0	193	15	1,074	85
10-12-2021	274,849	2,596	213,063	7,427	<5	0	202	12	1,462	88
11-12-2021	178,176	2,166	155,858	7,159	0	0	197	17	983	83
12-12-2021	178,068	3,087	167,670	7,669	<5	0	238	20	937	80
13-12-2021	261,259	4,380	232,666	11,221	13	1	391	29	961	70
14-12-2021	254,258	4,529	225,263	12,157	16	2	405	44	499	54
15-12-2021	225,026	4,744	219,477	11,940	13	1	544	48	587	51
16-12-2021	255,302	4,676	258,490	11,316	19	2	498	46	563	52
17-12-2021	273,106	4,550	236,644	11,831	20	4	272	53	222	43
18-12-2021	221,579	4,305	176,424	11,350	32	4	519	57	360	40
19-12-2021	220,878	5,263	182,974	11,637	49	4	680	59	426	37
20-12-2021	248,231	6,379	271,191	15,093	70	6	752	64	355	30
21-12-2021	251,443	6,408	258,469	14,778	62	7	561	67	216	26
22-12-2021	275,255	6,172	272,965	13,584	52	8	476	71	139	21
23-12-2021	277,452	5,037	246,286	14,573	65	9	513	70	156	21
24-12-2021	155,248	4,466	72,578	8,253	24	8	200	67	74	25
25-12-2021	128,703	4,787	73,516	9,163	45	12	264	72	56	15
26-12-2021	168,399	6,072	82,131	12,212	114	16	502	70	105	15
27-12-2021	207,265	7,393	186,664	24,968	342	17	1,399	71	231	12
28-12-2021	213,340	7,253	195,094	24,145	232	17	1,019	72	155	11
29-12-2021	238,567	6,813	216,571	19,207	79	19	300	72	38	9
30-12-2021	314,614	6,387	229,325	21,573	144	17	632	74	82	10
31-12-2021	181,564	4,507	72,615	10,978	86	22	281	70	32	8
01-01-2022	70,576	3,248	75,054	9,821	117	26	318	70	21	5
02-01-2022	224,366	8,394	156,448	22,461	1,073	22	3,447	72	250	5
03-01-2022	239,585	9,284	224,060	28,810	552	25	1,528	70	108	5
04-01-2022	260,020	8,579	207,726	27,044	88	25	248	71	15	4
05-01-2022	225,865	6,023	186,594	20,330	383	26	1,034	70	53	4
06-01-2022	247,962	5,205	212,979	17,996	255	32	525	65	26	3
07-01-2022	240,998	4,777	185,196	16,690	774	35	1,414	63	46	2
08-01-2022	145,731	3,999	136,728	15,682	266	37	437	61	15	2
09-01-2022	204,489	5,890	151,107	18,550	199	41	277	57	14	3
10-01-2022	242,588	6,932	211,919	26,243	449	44	556	55	12	1
11-01-2022	238,640	6,548	197,537	25,646	201	47	225	53	<5	0
12-01-2022	232,320	6,408	190,105	25,504	-	-	-	-	-	-
13-01-2022	255,218	7,167	225,495	26,775	-	-	-	-	-	-
14-01-2022	254,373	7,647	207,485	28,934	-	-	-	-	-	-
15-01-2022	158,305	6,738	158,450	28,218	-	-	-	-	-	-
16-01-2022	229,717	10,724	175,178	31,223	-	-	-	-	-	-
17-01-2022	275,634	11,886	251,447	45,876	-	-	-	-	-	-
18-01-2022	267,751	11,955	239,012	44,841	-	-	-	-	-	-
19-01-2022	250,051	10,857	226,241	42,031	-	-	-	-	-	-

Notes: This tables shows the number of antigen (AG) tests and RT-PCR tests in Denmark from 1 December 2021 to 19 January 2022. The table also provides information on the number of successfully sequenced positive RT-PCR tests by SARS-CoV-2 variant, including their relative proportion. On any given day, fewer than 5 of the successfully sequenced samples were classified as another variant than Omicron BA.2, Omicron BA.1, or Delta.

6.2 Sample selection to WGS

In Denmark, individuals can be tested in the community track (TestCenter Denmark) or in the healthcare track (Hospitals), which includes hospitalized patients, nursing home residents, and healthcare personnel (see Schønning et al. (2021) for elaboration). Only a proportion of all positive RT-PCR tests were sampled for whole genome sequencing (WGS). Both TestCenter Denmark and Hospitals sample positive RT-PCR tests randomly for WGS. However, all hospitalized patients were tested for SARS-CoV-2 and all positive tests were subject to WGS for treatment purposes. Figure 2 shows the sampling probability for WGS for within the study period by TestCenter Denmark and Hospitals. Panel a and b shows the sampling probability by age. For positive RT-PCR tests at TestCenter Denmark, there was no selection bias on age, whereas in hospitals, there was an increased sampling probability by age for young children and elderly. Panel c shows the sampling probability for WGS by sample Ct value for TestCenter Denmark (we only obtained Ct values from TestCenter Denmark). There was no sampling bias for Ct values <35. The probability of obtaining a successfully sequenced genome was correlated with the sample Ct value.

Figure 2: WGS sampling probability of positive RT-PCR tests

Notes: This figure shows the sampling probability of positive RT-PCR tests for WGS by testing place (TestCenter Denmark and Hospitals). Only Ct values from TestCenter Denmark were available. The shaded areas show the 95% confidence bands clustered on the household level.

7 Descriptive analyses

7.1 Summary statistics

In this section, we present additional summary statistics.

Table 5: Summary Statistics

	Omicron - BA.2				Omicron - BA.1			
	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)
Total, N	2,122	4,587	1,792	39	6,419	13,358	3,910	29
Sex, N								
Male	1,032	2,312	871	38	3,174	6,724	1,882	28
Female	1,090	2,275	921	40	3,245	6,634	2,028	31
Age, N								
0-10	180	799	336	42	302	2,280	747	33
10-20	523	845	289	34	1,468	2,556	673	26
20-30	484	633	240	38	1,714	2,056	633	31
30-40	328	573	321	56	958	1,408	595	42
40-50	241	804	303	38	784	2,393	650	27
50-60	225	660	213	32	692	1,838	400	22
60-70	79	175	61	35	324	572	145	25
70+	62	98	29	30	177	255	67	26
Household size, N								
2	790	790	345	44	2,577	2,577	853	33
3	517	1,034	378	37	1,605	3,210	862	27
4	550	1,650	683	41	1,504	4,512	1,379	31
5	212	848	292	34	606	2,424	667	28
6	53	265	94	35	127	635	149	23
Immunity, N								
Unvaccinated	449	1,210	518	43	1,016	3,421	1,171	34
Fully vaccinated / previous infection	1,114	1,917	783	41	3,781	5,921	1,856	31
Booster vaccinated	559	1,460	491	34	1,622	4,016	883	22

Notes: The secondary attack rate (SAR) is expressed as a percentage (%). Summary statistics based on primary cases are shown separately from summary statistics on potential secondary cases, positive secondary cases and SAR. The summary statistics stratified by the primary case level are presented in appendix Tables 6 and 7.

Table 6: Summary Statistics, stratified by primary case level

	Omicron - BA.2				Omicron - BA.1			
	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)
Total, N	2,122	4,587	1,792	39	6,419	13,358	3,910	29
Sex of primary case, %								
Male	49	49	49	38	49	50	49	29
Female	51	51	51	40	51	50	51	30
Age of primary case, %								
0-10	8	11	18	65	5	6	9	43
10-20	25	30	21	28	23	28	18	19
20-30	23	19	16	32	27	22	18	24
30-40	15	17	19	44	15	17	22	38
40-50	11	12	14	45	12	14	17	36
50-60	11	7	8	42	11	8	9	33
60-70	4	2	2	41	5	3	4	38
70+	3	1	2	42	3	1	2	37
Household size of primary case, %								
2	37	17	19	44	40	19	22	33
3	24	23	21	37	25	24	22	27
4	26	36	38	41	23	34	35	31
5	10	18	16	34	9	18	17	28
6	2	6	5	35	2	5	4	23
Immunity of primary case, %								
Unvaccinated	21	24	30	50	16	18	21	34
Fully vaccinated / previous infection	52	55	49	35	59	61	59	28
Booster vaccinated	26	22	21	38	25	21	20	28

Notes: The secondary attack rate (SAR) is expressed as a percentage (%). Potential and positive secondary cases are grouped based on the primary case characteristics. See Table 1 and appendix Table 5 for potential and positive secondary cases grouped by their own characteristics.

Table 7: Summary Statistics, stratified by primary case level

	Omicron - BA.2				Omicron - BA.1			
	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)	Primary Cases	Potential Secondary Cases	Positive Secondary Cases	SAR (%)
Total, N	2,122	4,587	1,792	39	6,419	13,358	3,910	29
Sex of primary case, N								
Male	1,032	2,270	873	38	3,174	6,643	1,928	29
Female	1,090	2,317	919	40	3,245	6,715	1,982	30
Age of primary case, N								
0-10	180	495	324	65	302	828	353	43
10-20	523	1,360	375	28	1,468	3,782	720	19
20-30	484	873	278	32	1,714	2,903	707	24
30-40	328	783	348	44	958	2,242	860	38
40-50	241	572	256	45	784	1,886	681	36
50-60	225	342	144	42	692	1,134	369	33
60-70	79	95	39	41	324	391	149	38
70+	62	67	28	42	177	192	71	37
Household size of primary case, N								
2	790	790	345	44	2,577	2,577	853	33
3	517	1,034	378	37	1,605	3,210	862	27
4	550	1,650	683	41	1,504	4,512	1,379	31
5	212	848	292	34	606	2,424	667	28
6	53	265	94	35	127	635	149	23
Immunity of primary case, N								
Unvaccinated	449	1,083	543	50	1,016	2,417	816	34
Fully vaccinated / previous infection	1,114	2,507	875	35	3,781	8,152	2,315	28
Booster vaccinated	559	997	374	38	1,622	2,789	779	28

Notes: The secondary attack rate (SAR) is expressed as a percentage (%). Potential and positive secondary cases are grouped based on the primary case characteristics. See Table 1 and appendix Table 5 for potential and positive secondary cases grouped by their own characteristics.

7.2 Testing dynamics, 14-day follow-up

In this section, we present evidence of the testing dynamics over a 14-day follow-up period. Figure 3 presents the probability of being tested and testing positive over a 14-day follow-up period instead of a 7-day follow-up period, as used in Figure 1. Figure 4 presents the SAR for households infected with the Omicron BA.1, BA.2, and Delta VOC, as well as those without an identified variant.

Figure 3: Probability of being tested and testing positive, 14-day follow-up

Notes: Panel (a) shows the probability of potential secondary cases being tested after a primary case has been identified within the household. Panel (b) shows the probability of potential secondary cases that test positive subsequently to a primary case being identified within the household. Note that the latter is not conditional on being tested, i.e. the denominator contains test negative individuals and untested individuals. The x-axes shows the days since the primary case tested positive, and the y-axes shows the proportion of individuals either being tested (a) or testing positive (b) with either antigen or RT-PCR tests, based on the subvariant of the primary case. The SAR for each day relative to the primary case can be read directly from panel (b). For example, the SAR on day 7 is 37% for BA.2 (red) and 30% for BA.1 (blue), whereas the SAR on day 14 is 42% and 35%, respectively. The shaded areas show the 95% confidence bands clustered on the household level. To allow for a 14-day follow-up, only primary cases with samples from 20 December 2021 to 5 January 2022 were included in this figure. Appendix Figure 4 also presents the 14-day SAR for the Delta VOC and those without a known variant.

Figure 4: Probability of testing positive, 14-day follow-up

Notes: This figure shows the probability of potential secondary cases that test positive subsequently to a primary case being identified within the household in a 14-day follow-up period. Note that the latter is not conditional on being tested, i.e. the denominator contains test negative individuals and untested individuals. The x-axis shows the days since the primary case tested positive, and the y-axis shows the proportion of individuals testing positive with either antigen or RT-PCR tests, based on the subvariant of the primary case. The SAR for each day relative to the primary case can be read directly from the figure. For example, the SAR on day 14 is 42% for Omicron BA.2, 35% for BA.1, 33% for those without a known variant, and 25% for Delta. The shaded areas show the 95% confidence bands clustered on the household level. To allow for a 14-day follow-up, only primary cases with samples from 20 December 2021 to 5 January 2022 were included in this figure.

7.3 Viral load of primary cases

This section provides descriptive statistics on the viral load of the primary case samples. Figure 5 shows the density plots of sample Ct values for primary cases infected with Omicron BA.1 and BA.2 stratified by their vaccination status. The distributional values are presented in Table 8. In particular, unvaccinated primary cases infected with BA.2 have a higher sample viral load (lower Ct value), with the median primary case having a 1.6 point lower sample Ct value, corresponding to 0.4 of a standard deviation.

Figure 5: Ct values of primary cases

Notes: This figure shows the density plots for primary cases infected with Omicron BA.1 and BA.2 stratified by their vaccination status.

Table 8: Ct values of primary cases

Vaccination status	Subvariant	Q1	Median	Q3	Mean	STD	N
Booster vaccinated	Omicron - BA.1	25.01	27.65	30.80	27.72	3.71	1,622
	Omicron - BA.2	24.48	27.09	30.06	27.20	3.82	559
	Difference / STD	-0.14	-0.14	-0.19	-0.13		
Fully vaccinated	Omicron - BA.1	24.65	27.33	30.48	27.50	3.76	3,781
	Omicron - BA.2	24.10	26.97	29.47	26.88	3.68	1,114
	Difference / STD	-0.15	-0.09	-0.26	-0.16		
Not vaccinated	Omicron - BA.1	24.14	27.02	29.97	27.20	3.91	1,016
	Omicron - BA.2	23.20	25.42	28.55	26.07	3.80	449
	Difference / STD	-0.24	-0.41	-0.36	-0.29		

Notes: This table provides distributional values for the Ct values of primary case samples. "Difference / STD" denotes the difference of primary cases with BA.2 and BA.1 relative to the standard deviation of BA.1 primary cases, within vaccination group.

8 Alternative presentation of main results

8.1 Contrasts

In this section, we present some of our main estimates in an alternative way, showing the estimates for comparison of different vaccination groups.

Figure 6 shows a full comparison of our main estimates across vaccination groups with different reference groups. We can see the relative effect of vaccination dependent on their vaccination status by choosing the *Contrast* (column) and compare their *Transmissibility* to the vaccination status of a similar primary case by choosing the *Reference* (row). For example, unvaccinated primary cases (Contrast=unvaccinated) compared to fully vaccinated primary cases (Reference=fully vaccinated) have an increased transmissibility of OR=1.13 when infected with BA.1 (blue) and OR=1.23 when infected with BA.2 (red). The interaction term of BA.2 on transmissibility has an OR=1.09 (black). This interaction term can be interpreted as the additional OR associated with BA.2 (relative to BA.1) within the comparison. Similarly, we can see the relative transmissibility for unvaccinated primary cases (Contrast=unvaccinated) compared to booster-vaccinated primary cases (Reference=booster). Primary cases with BA.1 have an OR=1.36 for transmissibility and primary cases with BA.2 have an OR=1.53 for transmissibility. The interaction term is OR=1.12. The estimates for *Susceptibility* is read in a similar way, but for potential secondary cases. Lastly, the *Combined* effect of vaccination shows the effect of both the primary case and potential secondary case having the same vaccination status. Thus, for households infected with BA.1, the OR=1.40 if both the primary case and potential secondary case are unvaccinated (Contrast=Unvaccinated) compared to when both are fully vaccinated (Reference=Fully vaccinated). Note, the model estimates for reference=Fully vaccinated are found in Table 10.

Table 9 shows the OR for infection with BA.2 compared to BA.1 for each combination of vaccination status of both the primary case and potential secondary case. The relative transmission of BA.2 compared to BA.1 is higher across all combinations of vaccination

431 groups. The relative transmission of BA.2 compared to BA.1 is generally higher for un-
432 vaccinated primary cases across all vaccination groups of potential secondary cases.
433 Table 10 shows the model estimates (similar to Table 12, model I) with interaction terms
434 instead of a full specification of contrasts.

Figure 6: Effect of vaccination, contrast plot

Notes: This figure shows a full comparison of our main estimates across vaccination groups with different reference groups. We can see the relative effect of vaccination dependent on their vaccination status by choosing the *Contrast* (column) and compare their *Transmissibility* to the vaccination status of a similar primary case by choosing the *Reference* (row). For example, unvaccinated primary cases (Contrast=unvaccinated) compared to fully vaccinated primary cases (Reference=fully vaccinated) have an increased transmissibility of OR=1.13 when infected with BA.1 (blue) and OR=1.23 when infected with BA.2 (red). The interaction term of BA.2 on transmissibility has an OR=1.09 (black). This interaction term can be interpreted as the additional OR associated with BA.2 (relative to BA.1) within the comparison. Note that the top/right subplots are simply the inverse of the lower/left subplots. 95%-confidence intervals. Standard errors are clustered on the household level.

Table 9: OR estimates of BA.2 compared to BA.1 by vaccination status

	Primary Case		
	Unvaccinated	Fully vaccinated	Booster-vaccinated
Potential secondary case			
Unvaccinated	1.31 (1.17-1.46)	1.21 (1.11-1.31)	1.17 (1.03-1.32)
Fully vaccinated	1.41 (1.27-1.55)	1.29 (1.23-1.36)	1.25 (1.13-1.38)
Booster-vaccinated	1.53 (1.35-1.73)	1.41 (1.31-1.52)	1.36 (1.23-1.51)

Notes: This table shows the OR for BA.2 compared to BA.1 for each combination of vaccination status of both the primary case and potential secondary case. 95% confidence intervals in parentheses. Standard errors clustered on the household level.

Method for estimating the contrast

To estimate the contrast, we used the estimates and variance-covariance matrix from the fitted model (Table 10) to generate 10,000 correlated Monte Carlo estimates of the model parameters. These estimates were then used to calculate log odds ratios representing the total effect of BA.2 compared to BA.1 for all possible pairwise contrasts within vaccination groups. This was done for transmissibility and susceptibility, as well as a combined effect calculated as the sum of these. In addition, the interaction between subvariant and vaccination group was also calculated for each pairwise contrast within vaccination groups. Results were summarised as mean and 95%-confidence intervals of the estimates, before exponentiation for interpretation as odds ratios (Figure 6). These analyses were performed in R version 4.1.2 (R Core Team, 2021).

Table 10: Model estimates

	Estimate	(95%-CI)
Intercept	-0.58	(-0.68;-0.48)
Omicron BA.2	0.26	(0.21;0.31)
Potential secondary case, vaccination status		
Booster-vaccinated	-0.27	(-0.35;-0.19)
Fully vaccinated	ref	(.)
Not-vaccinated	0.21	(0.13;0.29)
Primary case, vaccination status		
Booster-vaccinated	-0.19	(-0.28;-0.09)
Fully vaccinated	ref	(.)
Not-vaccinated	0.12	(0.02;0.22)
Potential secondary case, vaccination status		
Omicron BA.2 X Booster-vaccinated	0.08	(0.03;0.14)
Omicron BA.2 X Fully vaccinated	ref	(.)
Omicron BA.2 X Not-vaccinated	-0.07	(-0.13;-0.01)
Primary case, vaccination status		
Omicron BA.2 X Booster-vaccinated	-0.03	(-0.11;0.04)
Omicron BA.2 X Fully vaccinated	ref	(.)
Omicron BA.2 X Not-vaccinated	0.08	(0.01;0.16)
Primary case age		
0-10	0.30	(0.12;0.49)
10-20	-0.76	(-0.88;-0.64)
20-30	ref	(.)
30-40	-0.06	(-0.18;0.06)
40-50	0.09	(-0.03;0.21)
50-60	0.03	(-0.10;0.17)
60-70	0.38	(0.17;0.59)
70+	0.71	(0.38;1.04)
Potential secondary case age		
0-10	-0.11	(-0.23;0.02)
10-20	-0.12	(-0.22;-0.02)
20-30	ref	(.)
30-40	0.48	(0.37;0.58)
40-50	0.26	(0.16;0.36)
50-60	0.00	(-0.11;0.11)
60-70	-0.18	(-0.35;-0.01)
70+	-0.56	(-0.84;-0.27)
Household size		
2	0.27	(0.18;0.36)
3	-0.02	(-0.11;0.06)
4	0.07	(-0.01;0.15)
5	-0.08	(-0.19;0.03)
6	ref	(.)
Primary case sex		
Male	ref	(.)
Female	0.14	(0.07;0.20)
Potential secondary case sex		
Male	ref	(.)
Female	0.06	(-0.02;0.15)
Primary case sample date		
20DEC2021	-0.15	(-0.34;0.05)
21DEC2021	0.02	(-0.21;0.24)
22DEC2021	0.15	(-0.08;0.39)
23DEC2021	0.09	(-0.17;0.34)
24DEC2021	0.20	(-0.20;0.59)
25DEC2021	0.46	(0.12;0.80)
26DEC2021	0.20	(-0.08;0.47)
27DEC2021	0.06	(-0.10;0.23)
28DEC2021	-0.01	(-0.19;0.18)
29DEC2021	0.14	(-0.16;0.44)
30DEC2021	-0.04	(-0.26;0.18)
31DEC2021	ref	(.)
01JAN2022	-0.03	(-0.32;0.25)
02JAN2022	-0.05	(-0.16;0.05)
03JAN2022	-0.09	(-0.23;0.05)
04JAN2022	-0.16	(-0.48;0.15)
05JAN2022	-0.36	(-0.54;-0.19)
06JAN2022	-0.21	(-0.43;0.00)
07JAN2022	-0.15	(-0.29;-0.01)
08JAN2022	-0.09	(-0.32;0.14)
09JAN2022	0.00	(-0.24;0.24)
10JAN2022	-0.04	(-0.21;0.14)
11JAN2022	0.02	(-0.26;0.31)
Number of observations	17,945	
Number of households	8,541	

Notes: This table provides model estimates of our main specification (model 1) with an interaction effect. 95% confidence intervals are shown in parentheses. Standard errors are clustered on the household level.

9 Robustness

9.1 Model selection

Table 11: Model selection

Model	I	II	III	IV
AIC	21,245	21,249	21,260	21,263
Omicron BA.2 household	YES	YES	YES	YES
Potential secondary case vaccination status	YES	YES	YES	YES
Primary case vaccination status	YES	YES	YES	YES
Potential secondary case vaccination status X Omicron BA.2 household	YES	YES	NO	NO
Primary case vaccination status X Omicron BA.2 household	YES	NO	YES	NO
Primary case age	YES	YES	YES	YES
Potential secondary case age	YES	YES	YES	YES
Household size	YES	YES	YES	YES
Primary case sex	YES	YES	YES	YES
Potential secondary case sex	YES	YES	YES	YES
Number of observations	17,945	17,945	17,945	17,945
Number of households	8,541	8,541	8,541	8,541

Notes: This table provides estimates of the goodness of fit for the model. Model I includes an interaction with Omicron BA.2 both for susceptibility and transmissibility, and is the one used in the study. Model II includes an interaction with Omicron BA.2 only for susceptibility. Model III includes an interaction with Omicron BA.2 only for transmissibility. Model IV includes neither an interaction with Omicron BA.2 only for susceptibility nor transmissibility. AIC = Akaike information criterion.

9.2 Intra-household correlation of variants

An obvious concern in transmission studies is the linkage of primary cases to their potential secondary cases and positive secondary cases. In previous studies we have used the same method as in the current study (Lyngse et al., 2021a,b). In those studies, we investigated the household transmission between different SARS-CoV-2 variants and found an intra-household correlation of variants (i.e. the probability that a positive secondary case was infected with the same variant as the primary case) of 96-99%. In the present study, we are limited by only having a low number of positive secondary cases with a successfully sequenced genome. This is due to both the laboratory time needed from a positive test result to having a successfully sequenced genome from the sample and a relatively low sampling probability for WGS. Of all the 5,702 positive secondary samples in the current study, only 23 of them had a successfully sequenced genome at the time of analysis. All of these 23 samples were the exact same subvariant as the primary case, implying an intra-household correlation of subvariants of 100%.

9.3 Robustness of main results

This section provides additional analyses to investigate the robustness of our main results. Model I in Tables 12 and 13 provides the odds ratio (OR) estimates of our main model specification. In model II, we only include households with primary cases identified in the period 5-11 January 2022, in order to exclude the atypical transmission patterns between Christmas 2021 and New Year's Eve 2021/22. In model III, we only include households, where the primary cases have been identified by TestCenter Denmark to account for the potential sampling bias from the healthcare track (Section 6.2). In model IV, we only include households with two persons to account for the natural weighting bias from different sizes of households. In model V, we exclude households, where the primary case was below 10 years of age. In model VI, we exclude households that have previously been infected (defined by having a positive RT-PCR test), to exclude possible hybrid immunity (i.e. immunity from both vaccination and previous infection). In model VII, we only include positive secondary cases that tested positive on day 2-7 (in model I, this window is 1-7), as these could potentially be misclassified co-primary cases. Similarly, in model VIII, we only include positive secondary cases that tested positive on day 3-7. In model IX, we additionally adjust for the primary case sample Ct value, as differences in the viral load could potentially affect the results.

To investigate the sensitivity of our results presented in Table 3, we estimated our model by stratifying the sample (Table 14).

Table 12: Robustness I

Model	I		II		III		IV		V	
	OR	Main (95%-CI)	5-11 January (95%-CI)	OR	Only Test Center DK (95%-CI)	OR	2-person households (95%-CI)	OR	Primary cases >10years (95%-CI)	OR
Potential secondary case, vaccination status										
<i>Omicron BA.1 households</i>										
Booster-vaccinated	0.65	(0.58-0.73)	0.57	(0.46-0.70)	0.61	(0.54-0.70)	0.89	(0.71-1.12)	0.65	(0.58-0.73)
Fully vaccinated	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Not-vaccinated	1.23	(1.09-1.40)	1.27	(1.01-1.60)	1.24	(1.08-1.43)	0.97	(0.71-1.33)	1.20	(1.05-1.36)
<i>Omicron BA.2 households</i>										
Not-vaccinated	1.95	(1.37-2.78)	1.95	(1.19-3.20)	1.72	(1.16-2.55)	2.29	(1.00-5.23)	1.29	(0.84-2.00)
Fully vaccinated	2.45	(1.77-3.40)	2.46	(1.57-3.85)	2.04	(1.42-2.94)	2.36	(1.08-5.15)	1.70	(1.12-2.56)
Not-vaccinated	2.70	(1.95-3.74)	2.57	(1.63-4.03)	2.59	(1.81-3.72)	2.05	(1.01-4.17)	1.84	(1.23-2.75)
Primary case, vaccination status										
<i>Omicron BA.1 households</i>										
Booster-vaccinated	0.77	(0.67-0.88)	0.85	(0.65-1.12)	0.74	(0.63-0.86)	0.72	(0.57-0.90)	0.76	(0.66-0.87)
Fully vaccinated	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Not-vaccinated	0.93	(0.80-1.08)	1.11	(0.85-1.44)	0.94	(0.80-1.11)	1.00	(0.74-1.36)	0.96	(0.82-1.12)
<i>Omicron BA.2 households</i>										
Booster-vaccinated	0.47	(0.32-0.71)	0.55	(0.31-0.97)	0.51	(0.33-0.81)	0.52	(0.22-1.22)	0.69	(0.43-1.11)
Fully vaccinated	0.60	(0.42-0.85)	0.70	(0.42-1.14)	0.69	(0.47-1.01)	0.67	(0.30-1.48)	0.89	(0.58-1.36)
Not-vaccinated	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Primary case age										
0-10	2.69	(2.18-3.33)	2.29	(1.67-3.15)	2.43	(1.91-3.09)	2.27	(1.20-4.29)	-	-
10-20	0.93	(0.81-1.07)	0.83	(0.65-1.07)	0.92	(0.79-1.07)	0.72	(0.52-1.01)	0.91	(0.79-1.06)
20-30	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
30-40	1.88	(1.63-2.16)	1.59	(1.23-2.04)	1.90	(1.63-2.23)	1.19	(0.90-1.57)	1.85	(1.60-2.13)
40-50	2.19	(1.87-2.55)	1.40	(1.03-1.89)	2.15	(1.81-2.57)	1.67	(1.19-2.34)	2.15	(1.84-2.51)
50-60	2.06	(1.74-2.44)	1.46	(1.07-2.01)	2.06	(1.70-2.50)	2.04	(1.51-2.75)	2.04	(1.72-2.42)
60-70	2.90	(2.24-3.77)	2.55	(1.36-4.76)	2.99	(2.19-4.09)	2.16	(1.49-3.13)	2.83	(2.18-3.67)
70+	4.06	(2.73-6.03)	5.47	(2.30-13.05)	5.15	(3.16-8.39)	3.44	(2.09-5.68)	3.95	(2.66-5.87)
Potential secondary case age										
0-10	0.72	(0.61-0.84)	0.84	(0.64-1.10)	0.71	(0.60-0.85)	0.85	(0.54-1.34)	0.77	(0.65-0.90)
10-20	0.71	(0.62-0.81)	0.82	(0.64-1.04)	0.75	(0.64-0.87)	0.56	(0.38-0.82)	0.73	(0.64-0.84)
20-30	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
30-40	1.28	(1.11-1.48)	1.52	(1.19-1.94)	1.32	(1.12-1.55)	0.88	(0.65-1.19)	1.33	(1.15-1.55)
40-50	1.04	(0.90-1.19)	1.19	(0.93-1.51)	1.05	(0.90-1.23)	0.83	(0.61-1.15)	1.07	(0.92-1.24)
50-60	0.80	(0.69-0.92)	1.05	(0.80-1.37)	0.81	(0.69-0.96)	0.72	(0.53-0.97)	0.83	(0.72-0.97)
60-70	0.67	(0.53-0.83)	0.75	(0.49-1.15)	0.66	(0.51-0.85)	0.69	(0.48-0.99)	0.70	(0.56-0.88)
70+	0.46	(0.33-0.65)	0.37	(0.18-0.76)	0.53	(0.35-0.78)	0.44	(0.27-0.72)	0.48	(0.34-0.68)
Household size										
2	1.22	(1.08-1.37)	1.13	(0.92-1.40)	1.21	(1.07-1.38)	-	-	1.22	(1.09-1.38)
3	0.91	(0.82-1.01)	0.94	(0.78-1.13)	0.91	(0.81-1.03)	-	-	0.89	(0.80-1.00)
4	ref	(.)	ref	(.)	ref	(.)	-	-	ref	(.)
5	0.86	(0.75-0.99)	0.95	(0.76-1.19)	0.87	(0.75-1.01)	-	-	0.88	(0.76-1.02)
6	0.74	(0.58-0.93)	0.65	(0.43-0.98)	0.75	(0.57-0.98)	-	-	0.74	(0.57-0.95)
Primary case sex										
Male	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Female	1.15	(1.08-1.22)	1.13	(1.01-1.25)	1.16	(1.08-1.24)	1.18	(1.00-1.39)	1.15	(1.08-1.23)
Potential secondary case sex										
Male	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Female	1.07	(0.98-1.16)	1.08	(0.94-1.26)	1.07	(0.98-1.18)	1.02	(0.86-1.20)	1.07	(0.98-1.16)
Primary case sample date										
20DEC2021	0.81	(0.56-1.17)	-	-	0.89	(0.57-1.38)	0.86	(0.46-1.61)	0.79	(0.54-1.16)
21DEC2021	0.95	(0.65-1.41)	-	-	1.01	(0.63-1.62)	1.05	(0.54-2.04)	0.90	(0.60-1.35)
22DEC2021	1.10	(0.74-1.62)	-	-	1.21	(0.72-2.06)	0.91	(0.46-1.79)	1.09	(0.73-1.63)
23DEC2021	1.02	(0.68-1.54)	-	-	0.90	(0.55-1.46)	0.50	(0.25-1.01)	1.05	(0.69-1.60)
24DEC2021	1.14	(0.68-1.91)	-	-	0.98	(0.51-1.89)	0.59	(0.25-1.40)	0.97	(0.57-1.64)
25DEC2021	1.49	(0.93-2.39)	-	-	1.77	(0.91-3.43)	0.73	(0.31-1.73)	1.33	(0.81-2.19)
26DEC2021	1.14	(0.75-1.74)	-	-	0.87	(0.53-1.43)	0.79	(0.40-1.56)	1.10	(0.71-1.70)
27DEC2021	1.00	(0.70-1.43)	-	-	0.87	(0.58-1.31)	0.68	(0.38-1.23)	0.97	(0.68-1.40)
28DEC2021	0.93	(0.65-1.34)	-	-	0.86	(0.57-1.30)	0.65	(0.35-1.20)	0.91	(0.62-1.33)
29DEC2021	1.08	(0.69-1.67)	-	-	1.13	(0.68-1.87)	0.76	(0.36-1.59)	1.04	(0.66-1.64)
30DEC2021	0.90	(0.61-1.32)	-	-	0.77	(0.49-1.19)	0.80	(0.42-1.54)	0.86	(0.58-1.29)
31DEC2021	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
01JAN2022	0.91	(0.59-1.39)	-	-	0.80	(0.48-1.33)	0.97	(0.47-2.00)	0.84	(0.54-1.31)
02JAN2022	0.89	(0.64-1.24)	-	-	0.80	(0.55-1.16)	0.61	(0.35-1.07)	0.87	(0.62-1.22)
03JAN2022	0.86	(0.61-1.21)	-	-	0.76	(0.52-1.13)	0.70	(0.39-1.27)	0.84	(0.59-1.20)
04JAN2022	0.80	(0.51-1.25)	-	-	0.86	(0.50-1.49)	0.41	(0.18-0.94)	0.77	(0.48-1.22)
05JAN2022	0.65	(0.45-0.94)	0.68	(0.48-0.96)	0.59	(0.39-0.88)	0.40	(0.22-0.76)	0.64	(0.44-0.93)
06JAN2022	0.76	(0.52-1.11)	0.80	(0.56-1.15)	0.71	(0.46-1.08)	0.47	(0.24-0.90)	0.75	(0.50-1.12)
07JAN2022	0.81	(0.57-1.14)	0.85	(0.62-1.17)	0.74	(0.51-1.09)	0.63	(0.35-1.14)	0.76	(0.53-1.08)
08JAN2022	0.86	(0.58-1.27)	0.93	(0.64-1.34)	0.81	(0.52-1.26)	0.34	(0.16-0.73)	0.74	(0.48-1.13)
09JAN2022	0.94	(0.63-1.40)	0.99	(0.68-1.44)	0.81	(0.51-1.29)	0.86	(0.42-1.76)	0.91	(0.60-1.39)
10JAN2022	0.91	(0.63-1.30)	0.93	(0.66-1.30)	0.83	(0.55-1.24)	0.58	(0.30-1.11)	0.89	(0.61-1.31)
11JAN2022	0.96	(0.62-1.48)	ref	(.)	0.92	(0.58-1.45)	0.48	(0.21-1.11)	1.01	(0.64-1.60)
Number of observations	17,945		6,275		14,523		3,367		16,622	
Number of households	8,541		2,818		6,860		3,367		8,059	

Notes: This table provides model estimates for the main specification (model I) as well as different robustness specifications. 95% confidence intervals are shown in parentheses. Standard errors are clustered on the household level.

Table 13: Robustness II

Model	I		VI		VII		VIII		IX	
	OR	Main (95%-CI)	Excl. prev. HH infect. (95%-CI)		Cases day 2-7 (95%-CI)		Cases day 3-7 (95%-CI)		Control for Ct (95%-CI)	
Potential secondary case, vaccination status										
<i>Omicron BA.1 households</i>										
Booster-vaccinated	0.65	(0.58-0.73)	0.59	(0.52-0.66)	0.67	(0.60-0.76)	0.72	(0.62-0.82)	0.57	(0.47-0.68)
Fully vaccinated	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Not-vaccinated	1.23	(1.09-1.40)	1.07	(0.92-1.24)	1.24	(1.08-1.41)	1.17	(1.01-1.36)	1.14	(0.93-1.39)
<i>Omicron BA.2 households</i>										
Not-vaccinated	1.95	(1.37-2.78)	1.83	(1.24-2.71)	1.94	(1.34-2.82)	1.75	(1.17-2.60)	2.24	(1.31-3.83)
Fully vaccinated	2.45	(1.77-3.40)	2.56	(1.77-3.68)	2.30	(1.63-3.25)	2.02	(1.40-2.90)	2.29	(1.40-3.76)
Not-vaccinated	2.70	(1.95-3.74)	2.36	(1.65-3.36)	2.55	(1.81-3.59)	2.05	(1.42-2.97)	2.75	(1.65-4.60)
Primary case, vaccination status										
<i>Omicron BA.1 households</i>										
Booster-vaccinated	0.77	(0.67-0.88)	0.76	(0.65-0.88)	0.74	(0.64-0.85)	0.75	(0.64-0.88)	0.71	(0.56-0.89)
Fully vaccinated	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Not-vaccinated	0.93	(0.80-1.08)	0.95	(0.80-1.12)	0.93	(0.80-1.10)	0.93	(0.78-1.11)	0.94	(0.75-1.18)
<i>Omicron BA.2 households</i>										
Booster-vaccinated	0.47	(0.32-0.71)	0.45	(0.29-0.70)	0.52	(0.34-0.79)	0.63	(0.40-0.98)	0.33	(0.18-0.61)
Fully vaccinated	0.60	(0.42-0.85)	0.60	(0.41-0.88)	0.64	(0.45-0.92)	0.72	(0.49-1.05)	0.57	(0.34-0.97)
Not-vaccinated	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Primary case age										
0-10	2.69	(2.18-3.33)	2.66	(2.10-3.36)	2.74	(2.19-3.42)	2.96	(2.33-3.76)	2.23	(1.60-3.10)
10-20	0.93	(0.81-1.07)	0.87	(0.74-1.02)	0.98	(0.84-1.14)	1.02	(0.86-1.21)	0.85	(0.68-1.06)
20-30	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
30-40	1.88	(1.63-2.16)	1.84	(1.58-2.16)	1.88	(1.62-2.18)	1.94	(1.65-2.28)	1.66	(1.32-2.07)
40-50	2.19	(1.87-2.55)	2.15	(1.81-2.56)	2.01	(1.70-2.37)	1.98	(1.65-2.38)	1.86	(1.46-2.37)
50-60	2.06	(1.74-2.44)	2.08	(1.73-2.51)	1.98	(1.65-2.37)	2.02	(1.66-2.46)	1.80	(1.39-2.34)
60-70	2.90	(2.24-3.77)	2.86	(2.17-3.77)	2.61	(1.97-3.44)	2.51	(1.85-3.39)	2.72	(1.79-4.14)
70+	4.06	(2.73-6.03)	3.72	(2.46-5.64)	4.21	(2.78-6.38)	4.03	(2.62-6.21)	6.18	(2.87-13.32)
Potential secondary case age										
0-10	0.72	(0.61-0.84)	0.69	(0.58-0.83)	0.79	(0.67-0.93)	0.90	(0.75-1.08)	0.84	(0.65-1.08)
10-20	0.71	(0.62-0.81)	0.63	(0.54-0.74)	0.77	(0.67-0.89)	0.79	(0.67-0.93)	0.89	(0.72-1.10)
20-30	ref	(.)								
30-40	1.28	(1.11-1.48)	1.20	(1.03-1.40)	1.31	(1.12-1.52)	1.31	(1.11-1.54)	1.34	(1.07-1.67)
40-50	1.04	(0.90-1.19)	1.00	(0.85-1.17)	1.07	(0.92-1.25)	1.11	(0.94-1.31)	1.13	(0.90-1.40)
50-60	0.80	(0.69-0.92)	0.74	(0.63-0.87)	0.82	(0.70-0.97)	0.84	(0.70-1.00)	0.93	(0.74-1.17)
60-70	0.67	(0.53-0.83)	0.59	(0.47-0.75)	0.67	(0.53-0.85)	0.73	(0.56-0.94)	0.71	(0.49-1.02)
70+	0.46	(0.33-0.65)	0.44	(0.30-0.63)	0.49	(0.34-0.70)	0.52	(0.36-0.77)	0.53	(0.29-1.00)
Household size										
2	1.22	(1.08-1.37)	1.15	(1.02-1.31)	1.23	(1.09-1.40)	1.19	(1.04-1.36)	1.27	(1.06-1.52)
3	0.91	(0.82-1.01)	0.90	(0.80-1.01)	0.90	(0.80-1.02)	0.88	(0.77-0.99)	0.94	(0.80-1.11)
4	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
5	0.86	(0.75-0.99)	0.89	(0.76-1.04)	0.88	(0.76-1.01)	0.90	(0.77-1.04)	0.83	(0.67-1.02)
6	0.74	(0.58-0.93)	0.76	(0.57-1.01)	0.75	(0.59-0.97)	0.79	(0.61-1.03)	0.80	(0.56-1.15)
Primary case sex										
Male	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Female	1.15	(1.08-1.22)	1.16	(1.08-1.24)	1.14	(1.06-1.22)	1.12	(1.03-1.20)	1.14	(1.03-1.26)
Potential secondary case sex										
Male	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
Female	1.07	(0.98-1.16)	1.09	(0.99-1.19)	1.06	(0.97-1.16)	1.06	(0.96-1.16)	1.08	(0.95-1.23)
Primary case sample date										
20DEC2021	0.81	(0.56-1.17)	0.80	(0.54-1.18)	0.78	(0.54-1.14)	0.95	(0.63-1.45)	0.92	(0.53-1.57)
21DEC2021	0.95	(0.65-1.41)	0.95	(0.63-1.42)	0.86	(0.58-1.28)	1.06	(0.68-1.65)	1.20	(0.68-2.15)
22DEC2021	1.10	(0.74-1.62)	0.97	(0.64-1.47)	1.05	(0.71-1.58)	1.33	(0.85-2.09)	1.32	(0.64-2.72)
23DEC2021	1.02	(0.68-1.54)	1.02	(0.66-1.57)	0.98	(0.65-1.47)	1.23	(0.78-1.94)	0.81	(0.43-1.55)
24DEC2021	1.14	(0.68-1.91)	1.21	(0.70-2.09)	1.15	(0.68-1.94)	1.29	(0.73-2.26)	1.00	(0.49-2.05)
25DEC2021	1.49	(0.93-2.39)	1.53	(0.91-2.57)	1.37	(0.84-2.22)	1.51	(0.88-2.59)	1.16	(0.51-2.63)
26DEC2021	1.14	(0.75-1.74)	1.17	(0.75-1.84)	0.85	(0.55-1.30)	0.94	(0.58-1.53)	1.07	(0.61-1.88)
27DEC2021	1.00	(0.70-1.43)	1.00	(0.69-1.46)	0.77	(0.53-1.11)	0.88	(0.58-1.33)	0.96	(0.59-1.56)
28DEC2021	0.93	(0.65-1.34)	0.93	(0.63-1.37)	0.82	(0.56-1.20)	0.85	(0.55-1.31)	1.00	(0.61-1.64)
29DEC2021	1.08	(0.69-1.67)	1.05	(0.66-1.68)	0.79	(0.49-1.26)	0.98	(0.58-1.66)	1.34	(0.74-2.40)
30DEC2021	0.90	(0.61-1.32)	0.82	(0.54-1.23)	0.85	(0.57-1.27)	1.08	(0.69-1.69)	0.97	(0.56-1.69)
31DEC2021	ref	(.)	ref	(.)	ref	(.)	ref	(.)	ref	(.)
01JAN2022	0.91	(0.59-1.39)	1.03	(0.65-1.61)	0.75	(0.48-1.16)	0.83	(0.51-1.36)	0.94	(0.50-1.76)
02JAN2022	0.89	(0.64-1.24)	0.86	(0.61-1.22)	0.72	(0.52-1.01)	0.80	(0.55-1.17)	0.89	(0.57-1.39)
03JAN2022	0.86	(0.61-1.21)	0.86	(0.60-1.24)	0.68	(0.48-0.97)	0.85	(0.57-1.27)	0.79	(0.51-1.21)
04JAN2022	0.80	(0.51-1.25)	0.85	(0.53-1.36)	0.73	(0.45-1.18)	0.78	(0.45-1.36)	0.77	(0.40-1.46)
05JAN2022	0.65	(0.45-0.94)	0.66	(0.45-0.96)	0.62	(0.43-0.90)	0.74	(0.49-1.13)	0.70	(0.42-1.16)
06JAN2022	0.76	(0.52-1.11)	0.77	(0.51-1.17)	0.68	(0.45-1.00)	0.81	(0.52-1.26)	0.80	(0.49-1.32)
07JAN2022	0.81	(0.57-1.14)	0.80	(0.56-1.15)	0.81	(0.57-1.14)	0.96	(0.65-1.41)	0.87	(0.56-1.36)
08JAN2022	0.86	(0.58-1.27)	0.88	(0.58-1.33)	0.84	(0.56-1.24)	1.00	(0.64-1.55)	0.86	(0.53-1.40)
09JAN2022	0.94	(0.63-1.40)	0.96	(0.63-1.45)	0.84	(0.56-1.27)	0.95	(0.60-1.49)	1.00	(0.55-1.84)
10JAN2022	0.91	(0.63-1.30)	0.87	(0.59-1.27)	0.78	(0.54-1.13)	0.88	(0.58-1.34)	0.79	(0.47-1.30)
11JAN2022	0.96	(0.62-1.48)	1.01	(0.64-1.61)	0.81	(0.52-1.27)	0.95	(0.58-1.57)	1.04	(0.63-1.73)
Ct value										
16-18	-	-	-	-	-	-	-	-	1.76	(0.73-4.23)
18-20	-	-	-	-	-	-	-	-	1.57	(0.97-2.53)
20-22	-	-	-	-	-	-	-	-	1.31	(1.00-1.71)
22-24	-	-	-	-	-	-	-	-	1.51	(1.20-1.90)
24-26	-	-	-	-	-	-	-	-	1.15	(0.92-1.42)
26-28	-	-	-	-	-	-	-	-	1.04	(0.83-1.30)
28-30	-	-	-	-	-	-	-	-	ref	(.)
30-32	-	-	-	-	-	-	-	-	0.90	(0.70-1.15)
32-34	-	-	-	-	-	-	-	-	0.74	(0.57-0.98)
34-36	-	-	-	-	-	-	-	-	1.05	(0.60-1.81)
Number of observations	17,945		14,497		16,765		15,678		7,349	
Number of households	8,541		7,119		8,206		7,861		3,505	

Notes: This table provides model estimates for the main specification (model I) as well as different robustness specifications. 95% confidence intervals are shown in parentheses. Standard errors are clustered on the household level.

Table 14: Relative effect of Omicron BA.2 vs. BA.1, by stratification

	Susceptibility			Transmissibility		
	Unvaccinated	Fully vaccinated	Booster vaccinated	Unvaccinated	Fully vaccinated	Booster vaccinated
Omicron BA.2 households	2.74 (1.76-4.27)	1.99 (1.26-3.16)	3.54 (1.86-6.76)	3.92 (2.49-6.16)	1.59 (1.10-2.29)	1.11 (0.58-2.14)
Omicron BA.1 households	ref (.)	ref (.)	ref (.)	ref (.)	ref (.)	ref (.)
Number of observations	4,631	7,838	5,476	3,500	10,659	3,786
Number of households	3,030	5,391	4,084	1,465	4,895	2,181

Notes: This table provides model estimates similar to Table 3, but with stratification of the sample. For the susceptibility estimates, we stratify by the vaccination status of the potential secondary case. For the transmissibility estimates, we stratify by the vaccination status of the primary case. 95% confidence intervals are shown in parentheses. Standard errors are clustered on the household level.